Breaking News, Collaborations & Alliances

Ipsen and Skyhawk Therapeutics Collaborate on RNA Targeting Research

Aim to discover and develop small molecules for the treatment of rare neurological diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Ipsen and Skyhawk Therapeutics have signed an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.   The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will be responsible for all activities. Skyhawk’s platform accelerates building RNA-targeting small molecul...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters